strative 51,406 39,376 (a)
Depreciation 8,392 6,608
Amortization 1,382 993
Income from operations 20,482 13,867
Other income (expense) (329) 823
Income before income taxes 20,153 14,690
Provision for income taxes 8,326 5,482
Effective tax rate 41.3% 37.3%
Minority interest expense 296 128
Net income $11,531 $9,080
Earnings per common share:
Basic $0.41 $0.33
Diluted $0.40 $0.32
Shares used in computing earnings per
common share:
Basic 27,821 27,245
Diluted 28,648 27,970
Balance Sheet Information Preliminary
Dec 31, Sept 30, June 30,
2007 2007 2007
Billed accounts receivable, net $221,476 $205,002 $189,843
Unbilled accounts receivable, net 163,251 149,378 135,178
Deferred revenue (200,093) (173,972) (170,718)
Net receivables $184,634 $180,408 $154,303
Cash and marketable securities $62,926 $50,436 $96,677
Working capital $108,877 $75,958 $118,746
Total assets $809,549 $735,660 $680,013
Short-term borrowings $60,453 $55,463 $30,
'/>"/>
SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors2.
PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call3.
PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities4.
PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results5.
PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call6.
PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors7.
PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.8.
Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe9.
PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference10.
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis11.
Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues